[Anti-human IgG-dextran-adriamycin conjugate for immunotargeting of S180 sarcoma: effects on the tumor weight and survival time of the tumor-bearing mice].
To prepare anti-human IgG-dextran-adriamycin conjugate for immunotargeting of S180 sarcoma and assess its effects on the tumor weight and survival time of the tumor-bearing mice. Anti-human IgG-dextran- adriamycin was synthesized by conjugating dextran and adriamycin with anti-human IgG. The immunoactivity of anti-human IgG-dextran-adriamycin was measured by enzyme-linked immunosorbent assay (ELISA), and the cytotoxicity of anti-human IgG, adriamycin, and the IgG-dextran-adriamycin conjugate against the tumor cells in vitro was evaluated using MTT assay. In mice bearing S180 sarcoma, the agents were tested for their effects against tumor cell growth and the survival time of mice. The molar ratio of anti-mouse IgG, dextran, and adriamycin was 1:2.5:38 in the conjugate. The conjugates were shown to retain the immunoactivity of anti-human IgG, and possessed cytotoxicity to S180 cells in vitro. Administration of the conjugate and intratumor injection of human IgG resulted in a tumor suppression rate of 17.72%in mice bearing S180 sarcoma, but did not prolong the survival time of the mice. The anti-human IgG-dextran-adriamycin conjugate shows targeted antitumor effect against S180 sarcoma in mice.